Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

A physician survey finds a gap between guidelines and real-world clinical practice in treatment intensification for ...

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

Discover Baduanjin, a traditional Chinese exercise, and a potential complementary therapy for patients with prostate cancer ...